keyword
MENU ▼
Read by QxMD icon Read
search

mRcc

keyword
https://www.readbyqxmd.com/read/27924664/assessment-of-ethnic-differences-in-sunitinib-outcome-between-caucasian-and-asian-patients-with-metastatic-renal-cell-carcinoma-a-meta-analysis
#1
Xiaoyan Liu, Marta Fiocco, Jesse J Swen, Henk-Jan Guchelaar
BACKGROUND: An increasing number of studies have reported ethnic differences in sunitinib outcome in metastatic renal cell carcinoma (mRCC) patients. However, a comprehensive analysis is still lacking. Therefore, we systematically collected available published data and performed a meta-analysis to compare sunitinib efficacy and toxicity in Asian and Caucasian mRCC patients. METHODS: Data were extracted from published results from clinical trials, expanded access program and real-world clinical practice...
December 7, 2016: Acta Oncologica
https://www.readbyqxmd.com/read/27923360/tumour-response-in-metastatic-renal-cell-carcinoma-treated-with-tyrosine-kinase-inhibitors-assessment-of-intra-tumour-heterogeneity
#2
EDITORIAL
Viktoria Stühler, Jens Bedke
Intra-tumour heterogeneity is a common molecular phenomenon in metastatic clear cell renal carcinoma (mRCC), representing the genetic complexity of a tumour with multiple metastatic sites. The present commentary discusses the observed phenomena of phenotypic intra-tumour heterogeneity in mRCC patients treated with the tyrosine kinase inhibitors sunitinib or pazopanib. Here, drug response can be different on the level of each evaluated metastasis in the individual patient. This questions the currently used radiologic staging systems of RECIST criteria and demands for a modification of radiologic response assessment with the consequence of a patient-tailored therapy in the clinical setting...
December 7, 2016: BMC Medicine
https://www.readbyqxmd.com/read/27904651/sunitinib-in-the-treatment-of-metastatic-renal-cell-carcinoma
#3
REVIEW
Thomas A Schmid, Martin E Gore
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib received approval in 2006 and became a standard treatment option in the first-line treatment of metastatic renal cell cancer (mRCC) after a phase III trial showed superiority compared with interferon alpha (IFN-α). Sunitinib has also shown activity in second-line treatment in several trials. Most of the combination trials with sunitinib with various agents have led to considerable toxicity without improving efficacy...
December 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27904650/cabozantinib-in-the-treatment-of-advanced-renal-cell-carcinoma-clinical-trial-evidence-and-experience
#4
REVIEW
Jose Manuel Ruiz-Morales, Daniel Y C Heng
The treatment of metastatic renal cell carcinoma (mRCC) is rapidly changing. During first-line treatment with targeted therapy, patients ultimately develop resistance to therapy and the disease progresses. Recently, cabozantinib has demonstrated a better response rate, progression-free survival and overall survival compared with everolimus after failure of prior targeted therapy in patients with advanced or metastatic renal cell carcinoma (RCC). Cabozantinib is a small-molecule tyrosine kinase inhibitor (TKI)...
December 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27901483/meta-analysis-on-the-association-of-vegfr1-genetic-variants-with-sunitinib-outcome-in-metastatic-renal-cell-carcinoma-patients
#5
Xiaoyan Liu, Jesse J Swen, Epie Boven, Daniel Castellano, Hans Gelderblom, Ron H J Mathijssen, Cristina Rodríguez-Antona, Jesus García-Donas, Brian I Rini, Henk-Jan Guchelaar
VEGFR1 rs9582036 and rs9554320 were previously reported the association with sunitinib progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). Hereafter, the association of both single nucleotide polymorphisms (SNPs) with PFS/OS was confirmed in two independent mRCC cohorts. The aim of the current study was to validate the associations of both SNPs with sunitinib outcome in three independent well-characterized cohorts (SUTOX, CCF and SOGUG) including 286 sunitinib-treated mRCC patients, as well as to perform a meta-analysis of current and published data combined...
November 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/27891517/prognostic-significance-of-preoperative-neutrophil-to-lymphocyte-ratio-in-nonmetastatic-renal-cell-carcinoma-a-large-multicenter-cohort-analysis
#6
Seok-Soo Byun, Eu Chang Hwang, Seok Ho Kang, Sung-Hoo Hong, Jinsoo Chung, Tae Gyun Kwon, Hyeon Hoe Kim, Cheol Kwak, Yong-June Kim, Won Ki Lee
Background. The prognostic significance of the neutrophil-to-lymphocyte ratio (NLR) in nonmetastatic renal cell carcinoma (non-mRCC) is controversial, although NLR has been established as a prognostic factor in several cancers. The objective of our study was to assess the prognostic significance of preoperative NLR in non-mRCC, based on a large, multicenter cohort analysis. Methods. Totally, 1,284 non-mRCC patients undergoing surgery were enrolled from six institutions between 2000 and 2014. Recurrence-free survival (RFS) and cancer-specific survival (CSS) were calculated, and the prognostic significance of NLR was evaluated...
2016: BioMed Research International
https://www.readbyqxmd.com/read/27844145/presence-of-sarcomatoid-differentiation-as-a-prognostic-indicator-for-survival-in-surgically-treated-metastatic-renal-cell-carcinoma
#7
Liangyou Gu, Hongzhao Li, Hanfeng Wang, Xin Ma, Lei Wang, Luyao Chen, Wenlei Zhao, Yu Zhang, Xu Zhang
PURPOSE: To assess the prognostic significance of sarcomatoid differentiation for surgically treated metastatic renal cell carcinoma (mRCC). METHODS: Patients undergoing cytoreductive nephrectomy for mRCC in our center between 2006 and 2014 were included. All enrolled patients were separated into two groups according to the presence of sarcomatoid differentiation. Clinical and pathological variables were recorded. Student's t test or Chi-square test was applied to compare them...
November 14, 2016: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/27843746/prognostic-significance-of-platelet-lymphocyte-ratio-in-patients-receiving-first-line-tyrosine-kinase-inhibitors-for-metastatic-renal-cell-cancer
#8
Tae Ju Park, Yang Hyun Cho, Ho Seok Chung, Eu Chang Hwang, Sung-Hoon Jung, Jun Eul Hwang, Woo Kyun Bae, Jin Woong Kim, Suk Hee Heo, Young Hoe Hur, Seung Il Jung, Dong Deuk Kwon
BACKGROUND: The platelet-lymphocyte ratio (PLR) and neutrophil-lymphocyte ratio (NLR) have been reported as prognostic factors in various cancers, but their roles in metastatic renal cell cancer (mRCC) remain unclear. We investigated the significance of PLR and NLR, along with that of established prognostic factors, in mRCC patients receiving first-line tyrosine kinase inhibitors (TKI). METHODS: Data obtained from 63 mRCC patients who received first-line TKI between 2007 and 2013 were evaluated retrospectively...
2016: SpringerPlus
https://www.readbyqxmd.com/read/27825515/prognostic-value-of-neutrophil-to-lymphocyte-ratio-in-patients-with-metastatic-renal-cell-carcinoma-treated-with-first-line-and-subsequent-second-line-targeted-therapy-a-proposal-of-the-modified-imdc-risk-model
#9
Nobuyuki Tanaka, Ryuichi Mizuno, Yota Yasumizu, Keiichi Ito, Suguru Shirotake, Ayako Masunaga, Yujiro Ito, Yasumasa Miyazaki, Masayuki Hagiwara, Kent Kanao, Shuji Mikami, Ken Nakagawa, Tetsuo Momma, Takeshi Masuda, Tomohiko Asano, Masafumi Oyama, Mototsugu Oya
PURPOSE: The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model has been designed for prognostification in patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy. One factor is neutrophil count; however, increasing evidence has suggested the superiority of neutrophil-to-lymphocyte ratio (NLR) for predicting outcome. In this study, we evaluate the prognostic effect of NLR levels on patients with mRCC treated with targeted therapy, and then we compare the predictive accuracy of the IMDC risk model and its modified one by using NLR, instead of neutrophil count...
November 4, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27823651/first-line-antiangiogenics-for-metastatic-renal-cell-carcinoma-a-systematic-review-and-network-meta-analysis
#10
REVIEW
Benoît Rousseau, Emmanuelle Kempf, Gaelle Desamericq, Emilie Boissier, Marie Chaubet-Houdu, Charlotte Joly, Carolina Saldana, Helene Boussion, Cindy Neuzillet, Isabelle Macquin-Mavier, Stéphane Oudard, Laurent Salomon, Alexandre de la Taille, Christophe Tournigand
BACKGROUND: Sunitinib, pazopanib, sorafenib, axitinib and bevacizumab are the five recommended antiangiogenic agents in first-line therapy for metastatic renal cell carcinoma (mRCC). Because these drugs underwent simultaneous clinical development, no direct efficacy and safety comparison was ever conducted, thus preventing optimal therapy choices. METHODS: We performed a traditional and network meta-analysis to evaluate the efficacy and safety of mRCC-recommended first-line antiangiogenic agents...
November 2016: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/27822939/a-prospective-multicenter-trial-of-the-efficacy-and-tolerability-of-neoadjuvant-sunitinib-for-inoperable-metastatic-renal-cell-carcinoma
#11
Sung Han Kim, Seong Il Seo, Hyun Moo Lee, Han Yong Choi, Seung Hyun Jeon, Hyung Lae Lee, Tae Gyun Kwon, Yong June Kim, Wun Jae Kim, Jinsoo Chung
This study aimed to evaluate the efficacy, safety, and tolerability of 2-cycled neoadjuvant sunitinib therapy (NST) in patients with inoperable metastatic renal cell carcinoma (mRCC). Between 2009 and 2012, 14 patients with inoperable mRCC from 5 Korean academic centers were prospectively enrolled after collecting their clinicopathological data and completing health-related questionnaires. The best overall response (BOR), safety profile, and changes in quality of life during NST were assessed using the RECIST criteria (version 1...
December 2016: Journal of Korean Medical Science
https://www.readbyqxmd.com/read/27807800/establishment-of-a-mirna-mrna-regulatory-network-in-metastatic-renal-cell-carcinoma-and-screening-of-potential-therapeutic-targets
#12
Jie Zhu, Xin Ma, Yu Zhang, Dong Ni, Qing Ai, Hongzhao Li, Xu Zhang
This study aimed to screen effective diagnosis or treatment biomarkers for renal cell carcinoma, especially for metastatic renal cell carcinoma (mRCC) based on microRNA (miRNA) and messenger RNA (mRNA) genechip, and their regulatory network. The differential expressions of miRNAs and mRNAs were examined by miRNA and mRNA gene-chip analyses, respectively, in patients with either localized renal cell carcinoma (lRCC) or mRCC, and a miRNA-mRNA regulatory network was established. Subsequently, the regulation of selected mRNAs by miRNAs was validated by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and dual-luciferase reporter gene assay...
November 2, 2016: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/27802607/perturbative-universal-state-selective-correction-for-state-specific-multi-reference-coupled-cluster-methods
#13
Jiri Brabec, Subrata Banik, Karol Kowalski, Jiří Pittner
In this work, we report an extension of our previous development of the universal state-selective (USS) multireference coupled-cluster (MRCC) formalism. It was shown [Brabec et al., J. Chem. Phys. 136, 124102 (2012)] and [Banik et al., J. Chem. Phys. 142, 114106 (2015)] that the USS(2) approach significantly improves the accuracy of Brillouin-Wigner and Mukherjee MRCC formulations, however, the numerical and storage costs associated with calculating highly excited intermediates pose a significant challenge, which can restrict the applicability of the USS(2) method...
October 28, 2016: Journal of Chemical Physics
https://www.readbyqxmd.com/read/27784444/-efficacy-and-the-multivariate-analysis-of-sunitinib-as-first-line-treatment-in-patients-with-metastatic-renal-cell-carcinoma
#14
X L Chen, X N Sheng, Z H Chi, C L Cui, L Si, L L Mao, B X Tang, X Wang, B Lian, X Q Yan, Y Kong, J Guo
Objective: To investigate the efficacy and the influence factors of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma (mRCC). Methods: Clinical data of mRCC patients with sunitinib administered as the first line treatment from August 2008 to December 2015 were retrospectively reviewed. The efficacy and the influence factors of sunitinib treatment was analyzed using the Kaplan-Meier method and Cox proportional hazards models. Results: In all 166 patients who received sunitinib as first-line treatment, objective response rate was 31...
October 18, 2016: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/27777776/high-dose-interleukin2-a-10-year-single-site-experience-in-the-treatment-of-metastatic-renal-cell-carcinoma-careful-selection-of-patients-gives-an-excellent-outcome
#15
S Chow, V Galvis, M Pillai, R Leach, E Keene, A Spencer-Shaw, A Shablak, J Shanks, T Liptrot, F Thistlethwaite, R E Hawkins
BACKGROUND: VEGF-targeted therapy has become the mainstay of treatment for majority of mRCC patients. For most patients, benefit is short-lived and therefore treatment remains palliative in intent. HD IL2 is an effective immunotherapy treatment capable of durable remission in some patients but its unselected use has been difficult due to its modest response rate and considerable adverse effects. Using set pathology criteria as a selection tool in clinical practice, we have been able to show improved outcomes in our previous report...
2016: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/27771126/efficacy-of-second-line-targeted-therapy-for-renal-cell-carcinoma-according-to-change-from-baseline-in-international-metastatic-renal-cell-carcinoma-database-consortium-prognostic-category
#16
Ian D Davis, Wanling Xie, Carmel Pezaro, Frede Donskov, J Connor Wells, Neeraj Agarwal, Sandy Srinivas, Takeshi Yuasa, Benoit Beuselinck, Lori A Wood, D Scott Ernst, Ravindran Kanesvaran, Jennifer J Knox, Allan Pantuck, Sadia Saleem, Ajjai Alva, Brian I Rini, Jae-Lyun Lee, Toni K Choueiri, Daniel Y C Heng
BACKGROUND: We hypothesized that changes in International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic category at start of second-line therapy (2L) for metastatic renal cell carcinoma (mRCC) might predict response. OBJECTIVE: To assess outcomes of 2L according to type of therapy and change in IMDC prognostic category. DESIGN, SETTING, AND PARTICIPANTS: We performed a retrospective review of the IMDC database for mRCC patients who received first-line (1L) VEGF inhibitors (VEGFi) and then 2L with VEGFi or mTOR inhibitors (mTORi)...
October 19, 2016: European Urology
https://www.readbyqxmd.com/read/27768666/a-novel-therapy-to-promote-axonal-fusion-in-human-digital-nerves
#17
Ravinder Bamba, Thanapong Waitayawinyu, Ratnam Nookala, David Colton Riley, Richard B Boyer, Kevin W Sexton, Chinnakart Boonyasirikool, Sunyarn Niempoog, Nathaniel D Kelm, Mark D Does, Richard D Dortch, Robert Bruce Shack, Wesley P Thayer
BACKGROUND: Peripheral nerve injury can have a devastating impact on our military and veteran population. Current strategies for peripheral nerve repair include techniques such as nerve tubes, nerve grafts, tissue matrices, and nerve growth guides to enhance the number of regenerating axons. Even with such advanced techniques, it takes months to regain function. In animal models, polyethylene glycol (PEG) therapy has shown to improve both physiologic and behavioral outcomes after nerve transection by fusion of a portion of the proximal axons to the distal axon stumps...
November 2016: Journal of Trauma and Acute Care Surgery
https://www.readbyqxmd.com/read/27758076/clinical-significance-of-sunitinib-associated-macrocytosis-in-metastatic-renal-cell-carcinoma
#18
Maria T Bourlon, Dexiang Gao, Sara Trigero, Julia E Clemons, Kathryn Breaker, Elaine T Lam, Thomas W Flaig
Increases in the mean corpuscular volume (MCV) have been observed in patients with metastatic renal cell carcinoma (mRCC) on tyrosine kinase inhibitor (TKI) treatment; however, its association with progression-free-survival (PFS) is unknown. We aimed to characterize TKI-associated macrocytosis in mRCC and its relationship with PFS. Retrospective review of data on macrocytosis and thyroid dysfunction on mRCC patients treated with sunitinib and/or sorafenib. These results are evaluated in the context of our previous report on the association of hypothyroidism in this setting...
October 19, 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27754995/prognostic-role-of-the-cumulative-toxicity-in-patients-affected-by-metastatic-renal-cells-carcinoma-and-treated-with-first-line-tyrosine-kinase-inhibitors
#19
Roberto Iacovelli, Elena Verri, Maria Cossu Rocca, Gaetano Aurilio, Daniela Cullurà, Ottavio de Cobelli, Franco Nolè
Tyrosine kinase inhibitor-related toxicities have been reported to be predictive and/or prognostic factors in patients affected by metastatic renal cell carcinoma (mRCC). We aim to investigate the incidence of cumulative toxicity and its prognostic role in mRCC patients treated with sunitinib or pazopanib. mRCC patients treated with sunitinib or pazopanib at the European Institute of Oncology in Milan were reviewed for the incidence of adverse events. Cumulative toxicity was defined as the presence of more than one selected adverse event of any grade...
October 14, 2016: Anti-cancer Drugs
https://www.readbyqxmd.com/read/27742794/fcgr-polymorphisms-influence-response-to-il-2-in-metastatic-renal-cell-carcinoma
#20
Amy K Erbe, Wei Wang, Jacob Goldberg, Mikayla Gallenberger, KyungMann Kim, Lakeesha Carmichael, Dustin Hess, Eneida A Mendonca, Yiqiang Song, Jacquelyn A Hank, Su-Chun Cheng, Sabina Signoretti, Michael Atkins, Alexander Carlson, James W Mier, David J Panka, David F McDermott, Paul M Sondel
BACKGROUND: Fc-gamma receptors (FCGRs) are expressed on immune cells, bind to antibodies, and trigger antibody-induced cell-mediated anti-tumor responses when tumor-reactive antibodies are present. The affinity of the FCGR/antibody interaction is variable and dependent upon FCGR polymorphisms. Prior studies of cancer patients treated with immunotherapy indicate that FCGR polymorphisms can influence antitumor response for certain immunotherapies that act via therapeutically administered mAbs or via endogenous tumor-reactive antibodies induced from tumor antigen vaccines...
October 14, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
keyword
keyword
77808
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"